Tempest Therapeutics
↗Brisbane, California, USA
Tempest Therapeutics is a clinical-stage to early-stage biotechnology company developing small molecule therapeutics and cell therapies designed to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Originally founded in 2011, the company went public via IPO and now trades on NASDAQ under ticker TPST. The company pioneered tumor-targeted and immune-mediated approaches to oncology and recently underwent a strategic transformation through the acquisition of dual-targeting CAR-T programs from Factor Bioscience in February 2026. Tempest develops products targeting multiple cancer types including hepatocellular carcinoma, colorectal cancer, familial adenomatous polyposis, and hematologic malignancies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2011
Ownership:public
Status:operating
FUNDING
Stage:Public Company
Total Raised:$88.2M
Investors:Versant Ventures, F-Prime Capital, Quan Capital, Lilly Asia Ventures, Foresite Capital, Eight Roads Ventures
STOCK
Exchange:NASDAQ
Ticker:TPST
Market Cap:~$32M
PIPELINE
Stage:Phase 2 and Phase 3
Lead Drug Stage:Phase 3 ready (Amezalpat)
Modalities:Small molecule, CAR-T cell therapy, In vivo CAR-T
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:F. Hoffmann-La Roche Ltd. (supply of atezolizumab for Phase 3 amezalpat trial), Factor Bioscience (CAR-T asset acquisition, strategic investor), National Cancer Institute (Phase 2 funding for TPST-1495)
COMPETITION
Position:Emerging/Niche Player
Competitors:Jazz Pharmaceuticals, Moderna, BeiGene, Ayala Pharmaceuticals, Inovio Pharmaceuticals, Aura Biosciences, AVEO Oncology, CalciMedica +3 more
LEADERSHIP
Key Executives:
Matt Angel, Ph.D. - President & Chief Executive Officer
Stephen Brady - Chairman of the Board
Sam Whiting - Chief Medical Officer & Head of Research & Development
Nicholas Maestas - Chief Financial Officer & Head of Corporate Strategy
Darrin Bomba - Vice President, Development Operations
Sheldon Mullins - Vice President, Regulatory Affairs
Troy Wagner - Vice President, Quality Assurance
Lindsay Young - Head of Human Resources
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Tempest Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Tempest Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.